Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

Despite the initial successes of immunotherapy, there is an urgent clinical need for molecular assays that identify patients more likely to respond. Here, we report that ultrasensitive measures of circulating tumor DNA (ctDNA) and T-cell expansion can be used to assess responses to immune checkpoint...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2019-03, Vol.79 (6), p.1214-1225
Hauptverfasser:	Anagnostou, Valsamo, Forde, Patrick M, White, James R, Niknafs, Noushin, Hruban, Carolyn, Naidoo, Jarushka, Marrone, Kristen, Sivakumar, I K Ashok, Bruhm, Daniel C, Rosner, Samuel, Phallen, Jillian, Leal, Alessandro, Adleff, Vilmos, Smith, Kellie N, Cottrell, Tricia R, Rhymee, Lamia, Palsgrove, Doreen N, Hann, Christine L, Levy, Benjamin, Feliciano, Josephine, Georgiades, Christos, Verde, Franco, Illei, Peter, Li, Qing Kay, Gabrielson, Edward, Brock, Malcolm V, Isbell, James M, Sauter, Jennifer L, Taube, Janis, Scharpf, Robert B, Karchin, Rachel, Pardoll, Drew M, Chaft, Jamie E, Hellmann, Matthew D, Brahmer, Julie R, Velculescu, Victor E
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Immunological - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - pathology Circulating Tumor DNA - analysis Circulating Tumor DNA - genetics Cohort Studies DNA, Neoplasm - analysis DNA, Neoplasm - genetics Follow-Up Studies Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - immunology Lung Neoplasms - pathology Neoplasm, Residual - drug therapy Neoplasm, Residual - genetics Neoplasm, Residual - immunology Neoplasm, Residual - pathology Nivolumab - therapeutic use Prognosis Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!